• Recruiting

NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

Updated: May 25


NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

Observational

carfilzomib

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

ClinicalTrials.gov Identifier: NCT04827563


This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.


Sponsor:

University of Chicago

 

ClinicalTrials.gov Identifier: NCT01816971

Official Title: Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study


First Posted : April 1, 2021


Click here to see details on ClinicalTrials.gov

 

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Device: EndoPAT

Device: Blood Pressure Cuff

Diagnostic Test: Echocardiogram

Other: Quality of Life Assessment

Other: Blood Tests

 

Location

United States, Illinois



Posts Archive